TransCode Therapeutics (NASDAQ: RNAZ), a clinical-stage company developing immuno-oncology and RNA-based therapeutics for high-risk and advanced cancers, has announced the publication of a peer-reviewed article in Cancers reporting preclinical results for its lead therapeutic candidate, TTX-MC138, in a model of breast cancer bone metastasis. The findings highlight the potential of TTX-MC138 to address a critical unmet need in metastatic disease, where tumors spread to the bone and become difficult to treat.
The study demonstrated that TTX-MC138, when administered systemically, accumulated in metastatic bone lesions, reduced expression of microRNA-10b (miR-10b), and increased expression of the downstream tumor-suppressor target HOXD10. These molecular changes were associated with significant survival benefits compared with controls. Importantly, repeated dosing was well tolerated, with no observed systemic toxicity, suggesting a favorable safety profile for the candidate.
The results provide further validation for TransCode's approach of inhibiting miR-10b using its proprietary oligonucleotide nanotechnology. miR-10b is a well-documented biomarker of metastasis, and its overexpression is linked to aggressive tumor spread. By targeting this microRNA, TTX-MC138 aims to disrupt the metastatic process at a fundamental level.
The study's findings also suggest potential applicability across additional metastatic disease settings. Bone metastasis is a common and serious complication in advanced breast cancer, often leading to pain, fractures, and other skeletal-related events. Current treatments are largely palliative, underscoring the need for therapies that directly target the metastatic cascade.
TransCode Therapeutics is a clinical-stage company pioneering immuno-oncology and RNA therapeutic treatments for high-risk and advanced cancers. Its lead candidate, TTX-MC138, is focused on treating metastatic tumors that overexpress miR-10b. The company also has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells.
These preclinical results represent a significant step forward in the development of TTX-MC138 and support the company's ongoing efforts to advance the candidate into clinical trials. If successful, TTX-MC138 could offer a new option for patients with metastatic breast cancer, potentially improving outcomes and quality of life.
For more information on TransCode Therapeutics, visit the company's newsroom at https://ibn.fm/RNAZ.
For the full press release, see https://ibn.fm/E6gbq.
